Below Expected Outlook Pressured Boston Scientific (BSX) in Q1

1 hour ago 4

Soumya Eswaran

Wed, June 17, 2026 astatine 9:12 AM CDT 3 min read

Renaissance Investment Management, an concern absorption company, released its Q1 2026 "Large Cap Growth Strategy." A transcript of the missive tin beryllium downloaded here. Stocks fell sharply successful the archetypal 4th owed to the Iran conflict. The Energy and Materials sectors outperformed, Financials and Consumer Discretionary lagged. Large-cap stocks underperformed smaller-cap stocks, and Value outperformed Growth. The portfolio outperformed the S&P 500's -4.3% instrumentality but lagged the Russell 1000 Growth Index, which fell 9.8%. In this uncertain environment, the steadfast remains alert of the risks and emerging concern opportunities. In addition, you tin cheque the Strategy's apical 5 holdings for its champion picks for 2026.

In its first-quarter 2026 capitalist letter, Renaissance Investment Large Cap Growth Strategy highlighted Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) is simply a aesculapian exertion institution that manufactures and markets aesculapian devices for usage successful assorted interventional aesculapian specialties. On June 16, 2026, Boston Scientific Corporation (NYSE:BSX) closed astatine $46.92 per share. One-month instrumentality of Boston Scientific Corporation (NYSE:BSX) was -17.20%, and its shares mislaid 53.71% implicit the past 52 weeks. Boston Scientific Corporation (NYSE:BSX) has a marketplace capitalization of $69.74 billion.

Renaissance Investment Large Cap Growth Strategy stated the pursuing regarding Boston Scientific Corporation (NYSE:BSX) successful its Q1 2026 capitalist letter:

"Boston Scientific Corporation (NYSE:BSX) dropped contempt reporting coagulated operating results. The banal declined aft archetypal 2026 guidance came successful beneath expectations, driven by gross maturation deceleration successful its electrophysiology segment. This conception has contributed substantially to gross maturation successful the past, and the deceleration suggests that the company's main competitor, Medtronic, whitethorn beryllium gaining marketplace share."

Baird Maintains Bullish View connected Boston Scientific (BSX) Despite Lower Target

Boston Scientific Corporation (NYSE:BSX) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 110 hedge money portfolios held Boston Scientific Corporation (NYSE:BSX) astatine the extremity of the 4th quarter, up from 102 successful the erstwhile quarter. In the archetypal 4th of 2026, Boston Scientific Corporation (NYSE:BSX) delivered consolidated revenue of $5.203 billion, representing 11.6% year-over-year maturation compared to Q1 2025. While we admit the imaginable of Boston Scientific Corporation (NYSE:BSX) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article